当前位置： SCI文献检索 > International Journal of Chronic Obstructive Pulmonary Disease期刊下所有文献 > Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.

Abstract：

INTRODUCTION:Plasminogen activator inhibitor-1 (PAI-1), a major inhibitor of fibrinolysis, is associated with thrombosis, obesity, insulin resistance, dyslipidemia, and premature aging, which all are coexisting conditions of chronic obstructive pulmonary disease (COPD). The role of PAI-1 in COPD with respect to metabolic and cardiovascular functions is unclear. METHODS:In this study, which was nested within a prospective cohort study, the serum levels of PAI-1 were cross-sectionally measured in 74 stable COPD patients (Global Initiative for Chronic Obstructive Lung Disease [GOLD] Stages I-IV) and 18 controls without lung disease. In addition, triglycerides, high-density lipoprotein cholesterol, fasting plasma glucose, waist circumference, blood pressure, smoking status, high-sensitive C-reactive protein (hs-CRP), adiponectin, ankle-brachial index, N-terminal pro-B-type natriuretic peptide, and history of comorbidities were also determined. RESULTS:The serum levels of PAI-1 were significantly higher in COPD patients than in controls, independent of a broad spectrum of possible confounders including metabolic and cardiovascular dysfunction. A multivariate regression analysis revealed triglyceride and hs-CRP levels to be the best predictors of PAI-1 within COPD. GOLD Stages II and III remained independently associated with higher PAI-1 levels in a final regression analysis. CONCLUSION:The data from the present study showed that the serum levels of PAI-1 are higher in patients with COPD and that moderate-to-severe airflow limitation, hypertriglyceridemia, and systemic inflammation are independent predictors of an elevated PAI-1 level. PAI-1 may be a potential biomarker candidate for COPD-specific and extra-pulmonary manifestations.

journal_name

Int J Chron Obstruct Pulmon Dis

journal_title

International journal of chronic obstructive pulmonary disease

authors

Waschki B,Watz H,Holz O,Magnussen H,Olejnicka B,Welte T,Rabe KF,Janciauskiene S

doi

10.2147/COPD.S128689

subject

Has Abstract

pub_date

2017-03-22 00:00:00

pages

981-987

eissn

1176-9106

issn

1178-2005

pii

copd-12-981

journal_volume

pub_type

杂志文章

在线工具

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.